Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
Repeated daily inhalations of ciclesonide, compared to single inhalation, do not lead to increased systemic exposure Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhalerSource: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019 Year: 2020
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015
Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients? Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014
Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004